SCHEMBL21393035

SCHEMBL21393035

C=C/C=C(\OC=C)C(NC(=O)C=C)c1ccccc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
GFER P55789 1/20 0.35
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
HTT P42858 2/20 0.34
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ACHE P22303 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TGM2 P21980 1/20 0.33
MITF O75030 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21392918 0.71 KMT2A (0.48) LMNAMEN1KMT2AALDH1A1HPGD
SCHEMBL4774823 0.65 KMT2A (0.51) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL31048503 0.65 KMT2A (0.51) LMNAMEN1KMT2AALDH1A1TSHR
SCHEMBL28030413 0.64 TSHR (0.52) LMNAALDH1A1TSHRHTTTGM2
SCHEMBL1379751 0.64 SMN1; SMN2 (0.67) LMNAMEN1KMT2AALDH1A1HTT
SCHEMBL6128275 0.64 KMT2A (0.49) KMT2AALDH1A1HPGDL3MBTL1HTT
SCHEMBL895338 0.63 KDM4E (0.48) LMNAMEN1KMT2AALDH1A1HPGD
SCHEMBL205095 0.63 KMT2A (0.47) KMT2AALDH1A1HPGDL3MBTL1HTT
SCHEMBL2707685 0.63 KMT2A (0.47) KMT2AALDH1A1HPGDL3MBTL1HTT
SCHEMBL205096 0.63 KMT2A (0.47) KMT2AALDH1A1HPGDL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 LMNA 1016/4885MEN1 4319/4885KMT2A 3168/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 LMNA 1016/4885MEN1 4319/4885KMT2A 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.